This Subcommittee is the focal point for U.S. Government interagency efforts to prioritize and coordinate medical countermeasure acquisition programs. The WMD MCM Subcommittee considers a wide range of variables in their deliberations. These include the credibility and immediacy of the threat as determined by DHS material threat assessments (MTAs) and models of potential target populations and the settings in which the medical countermeasure would be used. It also evaluates the availability and suitability of current medical countermeasures and the products in the research and development pipeline. It considers utilization policies for potential medical countermeasures including the dosing schedule, the feasibility of deployment in a public health emergency and product shelf life and storage requirements. These factors, with others, form the basis of the U.S. Government's requirements. The Subcommittee is made up of Assistant Secretary-level officials from HHS, DoD, and DHS. Four Working Groups and a Steering Group serve the Subcommittee; these are the Chemical, Biological, Radiological/Nuclear, and Product Development Tools Working Groups and the Steering and Integration Group (STIG). (HHS, Pandemic and All-Hazards Preparedness Act Progress Report, November 2007, Appendix 2, WMD MCM Subcommittee)